The Johns Hopkins University

Other

Duke University

Virginia Commonwealth University

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Chinese Academy of Sciences

Northwestern University

University of Colorado

Oregon Health & Science University

Institute of Biotechnology Cas, V.v.i.

Martin Gilbert Pomper

Ronnie Charles Mease

Sangeeta Ray

Ying Chen

Xing Yang

Catherine Anne Foss

Il Minn

Sridhar Nimmagadda

Haofan Wang

Michael T McMahon

Steven M Rowe

Xiaolei Song

Hassan Shallal

Bert Vogelstein

Kenneth W Kinzler

Alan P Kozikowski

Paul B Fisher

Samuel Ray Denmeade

Shibin Zhou

Chetan Bettegowda

Michael R Zalutsky

Devanand Sarkar

Swadesh K Das

Robert Francis Dannals

Shawn Lupold

Seulki Lee

Mitchell E Menezes

Magdalena Scully

Hayden T Ravert

John L Musachio

Sachin S Chandran

Ganesan Vaidyanathan

Hong Fan

Andrew Horti

Thomas J Meade

Pankaj Jay Pasricha

Hai-Quan Mao

Jun O Liu

V Michael Holers

Jordan J Green

Joshua M Thurman

Michael S Yu

Biao Yu

Curtis R Chong

Jose Luis Santos

Yong Ren

Allen Yi-Lan Wang

Richard F Ambinder

Jiazhong Zhang

Wojciech Lesniak

Mark Castanares

Stephanie Slania

Yong Du

Kevin H Leung

Vivek Kumar

Tomas R Guilarte

Daniel P Holt

Ray Sangeeta

Matthew W Rotz

Zaver Bhujwalla

Nikita Oskolkov

Sanjay K Jain

Mohamad Allaf

Alvaro A Ordonez

Zhihang Chen

Nabil J Alkayed

Samit Chatterjee

Dhiraj Kumar

Hannah Vaughan

Edward A Weinstein

Michael Gorin

Camila Gadens Zamboni

Michael Michaelides

Feng Hu

Juan Luis Gomez

Marta Sanchez-Soto

Ogyi Park

Jordi Bonaventura

Zora Novakova

Cyril Barinka

Mariah Klunk

Ishan Barman

Qiaoling Wang

Ming Li

John Michael Williford

Jun Liu

Qingli He

Jong-Sung Park

Yang Li

Yumin Oh

Daniel Summerfield

Maani Archang

Maureen Horton

Steven D Leach

Cong Li

Marie-France Penet

Matthew Rotz

Magdalena Swierczewska

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

Provided herein are methods of generating models to predict prospective pathology scores of test subjects having a pathology in certain embodiments. Related systems and computer program products are also provided.

Methods and related aspects for pathology prognosis

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) and their use in imaging and treating FAP-α related diseases and disorders are disclosed.

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)

Methods, reporter gene constructs, and kits for using prostate-specific membrane antigen (PSMA) as an imaging reporter to image a variety of cells and tissues are provided.

PSMA-based molecular-genetic reporter system

Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.

PSMA-binding agents and uses thereof

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

PSMA targeted fluorescent agents for image guided surgery

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)

Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.

Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy

The present invention provides a targeted nanoplex platform for in vivo imaging and theranostic imaging of cancer to simultaneously provide non-invasive assessment of tumor burden and cancer-selective treatments.

Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo

Methods, and related compositions, for the improved synthesis of [F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [F]DCFPyL so produced.

Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [F]DCFPYL

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.

Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)

Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.

DREADD actuators

Growing community of inventors

Baltimore, MD, United States of America

Martin Gilbert Pomper